Syngene’s ‘first-time-right’ Technology Transfer approach to achieve timely clinical and commercial milestones.

How to manage the risk of drug-drug interactions in drug development and during poly therapy especially with elderly patients.

Demonstrating the therapeutic edge of targeting CEACAM7 in pancreatic cancer using an integrative approach between biology and bioinformatics.